Clinical Trials Logo

Osteoarthritis, Knee clinical trials

View clinical trials related to Osteoarthritis, Knee.

Filter by:

NCT ID: NCT06267053 Completed - Knee Osteoarthritis Clinical Trials

Relationship Between Vitamins and Radiologic Stage in Knee Osteoarthritis

Start date: December 1, 2023
Phase:
Study type: Observational

The aim of this study is to investigate the relationship between folic acid, vitamin B12 and 25-OH vitamin D levels and radiographic staging in patients diagnosed with primary gonarthrosis.

NCT ID: NCT06254976 Completed - Clinical trials for Osteoarthritis of Knee

Serum Nesfatin-1 and Human Cartilage Glycoprotein-39 Levels in Knee Osteoarthritis

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

In this study, our objective was to assess the correlation between serum human cartilage glycoprotein-39 (YKL-40) and nesfatin-1 values, the patient's clinical condition, ultrasonographic cartilage thickness measurements, and the response to PRP treatment in knee osteoarthritis (OA)

NCT ID: NCT06233955 Completed - Knee Osteoarthritis Clinical Trials

Effect of Maitland Mobilization With Low Level Laser Therapy in Treatment of Patients With Knee Osteoarthritis

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

Background: Osteoarthritis is a common cause of chronic pain and disability in elderly people. Objective: To evaluate the efficacy of low-level laser therapy (LLLT) in combination with Maitland mobilization and conventional physical therapy in patients with chronic knee osteoarthritis. Design: Pre-test post-test randomized control trial.

NCT ID: NCT06228911 Completed - Clinical trials for Osteoarthritis, Knee

Increased Blood Glucose Levels After Steroid Injection

Start date: January 15, 2020
Phase: N/A
Study type: Interventional

a sample of 600 patients diagnosed as Knee osteoarthritis injected with 40 mg triamcinolone, recorded their morning fasting blood glucose levels for 7 days before injection used as the baseline blood glucose level, which was compared with FBS levels for 14 days after steroid injection. Our study compared the differences in blood glucose changes between HbA1c >7% and HbA1c ≤7% groups and those between insulin and non-insulin treated groups.

NCT ID: NCT06228274 Completed - Knee Osteoarthritis Clinical Trials

Assessment of Safety and Efficacy of ARTHRUM 2.5% for Treatment of Painful Osteoarthritis of the Knee

ART-ONE75
Start date: March 2013
Phase:
Study type: Observational

ARTHRUM 2.5% MONO-INJECTION as symptomatic treatment by joint injection extends the conservative therapeutic arsenal in Knee osteoarthritis. The reduction of functional limits and disabilities induced by knee osteoarthritis as well as improvement of quality of life of patients is a public health need registered amongst the priorities established by the French law of 9 August 2004 relative to Public Health policy. However, the response to this need is not limited to treatment with health products. This prospective, open, multi-centre trial of the real-life efficacy of ARTHRUM 2.5% aims to demonstrate the efficacy of a single joint injection of this treatment on pain, during 6 months, in the symptomatic treatment of patients suffering from Knee osteoarthritis

NCT ID: NCT06211465 Completed - Clinical trials for Cardiovascular Diseases

Cardiovascular And Metabolic Risk After Arthroplasty

CAMERA
Start date: March 1, 2014
Phase:
Study type: Observational

Osteoarthritis is a chronic joint disease that lacks curative therapy. Epidemiological studies show increase in the burden of disease. Total joint arthroplasty is one of the best treatment options for end-stage osteoarthritis. However, the specific effects of total joint arthroplasty on cardiovascular risk and metabolic profile are largely unknown. The aim of this project is to elucidate how hip and knee total joint arthroplasty impacts cardiovascular risk and metabolomic profile in comparison with general population. We hypothesize that arthroplasty decreases pain, systemic inflammation levels and increases functional status that all lead to decreased metabolic and cardiovascular risk.

NCT ID: NCT06202170 Completed - Knee Osteoarthritis Clinical Trials

Validity and Reliability of 30SFPW Test Patients With TKA

Start date: January 2, 2023
Phase:
Study type: Observational [Patient Registry]

Walking speed after total knee arthroplasty (TKA) can be used as a simple tool to monitor postoperative recovery. There are different protocols for gait assessment in patients with TKA. The 30 Second Fast Walk Test (30SFW) is a simple, low-cost and easy-to-apply assessment method that requires very little equipment in clinical settings. 30SFW is a reliable, valid test of walking ability in patients with knee osteoarthritis (OA). Objective: To investigate the reliability and validity of the 30SFW test in the evaluation of gait in patients with TKA.

NCT ID: NCT06201637 Completed - Knee Osteoarthritis Clinical Trials

Validity And Reliability Of The Short Physical Performance Battery In Patients Undergoing Total Knee Arthroplasty

Start date: January 2, 2022
Phase: N/A
Study type: Interventional

Objectives: Practical, applicable, valid, and reliable tools are needed to assess physical performance in patients with Total Knee Arthroplasty(TKA) in a variety of settings, including routine clinical assessment, research studies, and community-based programs. Therefore, the aim of this study is to evaluate the validity and reliability of the Short Physical Performance Battery (SPPB) among patients with TKA. Methods: We included patients who underwent TKA surgery. The SPPB, Timed up and go(TUG) test and, Hospital for Special Surgery (HSS) Knee Score were administered to the patients. SPPB was performed twice on the same day with 1 h rest.

NCT ID: NCT06196021 Completed - Knee Osteoarthritis Clinical Trials

Effects of Hyaluronic Acid Injection and Exercise Treatments in Knee Osteoarthritis

Start date: March 1, 2006
Phase: N/A
Study type: Interventional

Background: Osteoarthritis (OA) is one of the most common joint diseases that most often causes physical disability. Physical therapy modalities, exercise programs and intra-articular injections are widely used in the treatment of OA. Purpose: The aim of this study is to investigate the effects of adding different exercise treatments to hyaluronan injection on proprioception, muscle strength and quality of life in patients with knee OA. Methods: A total of 54 patients were included in the study and were randomized into three groups. Quadriceps strengthening exercises were applied to the patients in Group 1, a home exercise program was applied to the patients in Group 2, and no exercise program was applied to the patients in Group 3. Additionally, all patients received patient education and intra-articular hyaluronic acid injection into the symptomatic knee. Standard forms were filled out to evaluate the patients' pain, functional status and quality of life. Muscle strength and proprioception were evaluated with an isokinetic dynamometer. Changes in the patients' walking parameters were evaluated by gait analysis. Evaluations were made at the beginning of treatment, at the end of treatment, and at the 3rd and 6th months of treatment.

NCT ID: NCT06184685 Completed - Clinical trials for Primary Knee Osteoarthritis

Safety and Efficacy of Sahasthara ME vs Diclofenac ME for Treating Primary Knee Osteoarthritis

Start date: October 20, 2021
Phase: Phase 2
Study type: Interventional

Background: Sahasthara is a traditional Thai herbal remedy used for the anti-inflammatory treatment of the musculoskeletal system, while diclofenac sodium is one of the most topically administered anti-inflammatory drug. However, there has not been scientifically researched regarding the efficacy and safety of SHT formulated as ME. Purpose: To assess the safety and effectiveness of Sahasthara microemulsion (SHT-ME) in comparison to a diclofenac microemulsion (DF-ME) in treating primary osteoarthritis (OA) of the knee. Methods: A randomized, double blinded clinical trial phase II was conducted. One treatment group received 1% SHT-ME, while the other received 2% DF-ME (2 ml, 3 times per day for 28 days) on their affected knee area. All patients were followed up at 14 and 28 days. Changes in the visual analogue scale (VAS) for pain as well as 100-meter walking times, the WOMAC index scores, and a global assessment were examined for efficacy. Clinical examinations, abnormalities in laboratory tests, and the incidence of adverse events (AEs) were assessed for safety.